Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of Prucalopride in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by:
Movetis
ClinicalTrials.gov Identifier:
NCT00793429
First received: November 18, 2008
Last updated: November 20, 2008
Last verified: November 2008

November 18, 2008
November 20, 2008
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00793429 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety Study of Prucalopride in Healthy Volunteers
A Double-Blind, Placebo-Controlled, Two-Way Cross-Over in Healthy Volunteers, to Evaluate the Pharmacokinetics, Tolerability and Cardiac Safety of Prucalopride at Steady-State

In this study healthy volunteers received increasing doses of prucalopride to study the tolerability and cardiac safety of prucalopride. The study hypothesis was that prucalopride at doses up to 10 mg has no clinically relevant effect on the cardiovascular safety in healthy volunteers.

Single-centre, double-blind, placebo-controlled, cross-over study in 33 healthy volunteers with 2 sessions. Each session consisted of a run-in day for baseline assessments, 8 treatment days and 5 additional days for followup assessments. Subjects were randomised to start with either the prucalopride or placebo session. The prucalopride dose was consecutively escalated in 2 mg steps per day, starting from 2 mg up to 10 mg once daily If a subject did not tolerate the 10- or 8-mg dose, 1 step back in the dosage scheme was allowed, from 10 to 8 mg on Day 6, or from 8 to 6 mg on Day 5. Subjects with intolerance for doses of less than 6 mg, were withdrawn from the study. Repeated dosing (6, 8 or 10 mg) was continued once daily until Day 8, to achieve steady-state. During placebo, the number of placebo tablets was consecutively escalated in an identical way as described for prucalopride. Between the 2 sessions, there was a washout period of 14 to 21 days, to avoid any carry-over effect.

Interventional
Phase 1
Not Provided
Healthy
  • Drug: Prucalopride
  • Other: Placebo
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Aged between 18 and 45 years.
  • Normal weight.
  • Healthy on the basis of a pre-study physical examination, medical history, anamnesis,ECG, 24-hour Holter monitoring, echocardiogram and the results of blood biochemistry and haematology tests and a urinalysis carried out in 3 weeks preceding randomisation.

Exclusion Criteria:

  • History or suspicion of alcohol, barbiturate, amphetamine or narcotic abuse.
  • Smoking more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 6 months prior to selection.
  • History of cardiac arrhythmias, bronchospastic or cardiovascular disease (e.g. ischaemic heart disease or cerebrovascular accident), diabetes mellitus, thyrotoxicosis,Parkinsonism.
  • Presence of prolonged QTc (Bazett) on ECG at screening (QTc >450 ms in male subjects, QTc >470 ms in female subjects).
  • Use of concomitant medication, except for oral contraceptives and paracetamol.
  • Participation in an investigational drug study in 30 days prior to the first visit.
  • Donation of blood in the 60 days preceding the first visit.
  • Pregnancy or breast-feeding female.
  • Female subjects of childbearing potential without adequate contraceptive protection during the study.
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00793429
GBR-9
No
Not Provided
Movetis
Not Provided
Not Provided
Movetis
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP